UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Nuclear export of proteins and drug resistance in cancer

Biochemical pharmacology, 2012-04, Vol.83 (8), p.1021-1032

2012

Volltextzugriff (PDF)

First-in-Man Clinical Trial of the Oral Pan-AKT Inhibitor MK-2206 in Patients With Advanced Solid Tumors

Journal of clinical oncology, 2011-12, Vol.29 (35), p.4688-4695

2011

Volltextzugriff (PDF)

Randomized multicenter phase 2 study of pomalidomide, cyclophosphamide, and dexamethasone in relapsed refractory myeloma

Blood, 2016-05, Vol.127 (21), p.2561-2568

2016

Volltextzugriff (PDF)

Phase I Trial of Interleukin-12 Plasmid Electroporation in Patients With Metastatic Melanoma

Journal of clinical oncology, 2008-12, Vol.26 (36), p.5896-5903

2008

Volltextzugriff (PDF)

Canonical Wnt pathway inhibitor ICG-001 induces cytotoxicity of multiple myeloma cells in Wnt-independent manner

PloS one, 2015-01, Vol.10 (1), p.e0117693-e0117693

2015

Volltextzugriff (PDF)

Inhibition of Notch signaling induces apoptosis of myeloma cells and enhances sensitivity to chemotherapy

Blood, 2008-02, Vol.111 (4), p.2220-2229

2008

Volltextzugriff (PDF)

Phase II Study of the Mitogen-Activated Protein Kinase 1/2 Inhibitor Selumetinib in Patients With Advanced Hepatocellular Carcinoma

Journal of clinical oncology, 2011-06, Vol.29 (17), p.2350-2356

2011

Volltextzugriff (PDF)

Treatment of acquired drug resistance in multiple myeloma by combination therapy with XPO1 and topoisomerase II inhibitors

Journal of hematology and oncology, 2016-08, Vol.9 (1), p.73-11, Article 73

2016

Volltextzugriff (PDF)

ABCG2 expression, function, and promoter methylation in human multiple myeloma

Blood, 2006-12, Vol.108 (12), p.3881-3889

2006

Volltextzugriff (PDF)

Valproic acid alters chromatin structure by regulation of chromatin modulation proteins

Cancer research (Chicago, Ill.), 2005-05, Vol.65 (9), p.3815-3822

2005

Volltextzugriff (PDF)

Human Multiple Myeloma Cells Are Sensitized to Topoisomerase II Inhibitors by CRM1 Inhibition

Cancer research (Chicago, Ill.), 2009-09, Vol.69 (17), p.6899-6905

2009

Volltextzugriff (PDF)

Spending and Job-Finding Impacts of Expanded Unemployment Benefits: Evidence from Administrative Micro Data

The American economic review, 2024-09, Vol.114 (9), p.2898-2939

2024

Volltextzugriff (PDF)

Selective inhibition of matrix metalloproteinase-2 in the multiple myeloma-bone microenvironment

Oncotarget, 2017-06, Vol.8 (26), p.41827-41840

2017

Volltextzugriff (PDF)

Potentiation of a Topoisomerase I Inhibitor, Karenitecin, by the Histone Deacetylase Inhibitor Valproic Acid in Melanoma: Translational and Phase I/II Clinical Trial

Clinical cancer research, 2009-04, Vol.15 (7), p.2479-2487

2009

Volltextzugriff (PDF)

A Phase 1 Escalating Single-Dose and Weekly Fixed-Dose Study of Cetuximab: Pharmacokinetic and Pharmacodynamic Rationale for Dosing

Clinical cancer research, 2007-02, Vol.13 (3), p.986-993

2007

Volltextzugriff (PDF)

Sequence-specific potentiation of topoisomerase II inhibitors by the histone deacetylase inhibitor suberoylanilide hydroxamic acid

Journal of cellular biochemistry, 2004-05, Vol.92 (2), p.223-237

2004

Volltextzugriff (PDF)

Phase I Trial of Poly-l-Glutamate Camptothecin (CT-2106) Administered Weekly in Patients with Advanced Solid Malignancies

Clinical cancer research, 2007-10, Vol.13 (19), p.5855-5861

2007

Volltextzugriff (PDF)

CRM1 Inhibition Sensitizes Drug Resistant Human Myeloma Cells to Topoisomerase II and Proteasome Inhibitors both In Vitro and Ex Vivo

Journal of Cancer, 2013-01, Vol.4 (8), p.614-625

2013

Volltextzugriff (PDF)

Combined inhibition of Notch signaling and Bcl-2/Bcl-xL results in synergistic antimyeloma effect

Molecular cancer therapeutics, 2010-12, Vol.9 (12), p.3200-3209

2010

Volltextzugriff (PDF)

CRM1-mediated nuclear export of proteins and drug resistance in cancer

Current medicinal chemistry, 2008-11, Vol.15 (26), p.2648-2655

2008

Volltextzugriff (PDF)

Inhibition of CRM1-dependent nuclear export sensitizes malignant cells to cytotoxic and targeted agents

Seminars in cancer biology, 2014-08, Vol.27, p.62-73

2014

Volltextzugriff (PDF)

Novel 5' untranslated region variants of BCRP mRNA are differentially expressed in drug-selected cancer cells and in normal human tissues : Implications for drug resistance, tissue-specific expression, and alternative promoter usage

Cancer research (Chicago, Ill.), 2006-05, Vol.66 (10), p.5007-5011

2006

Volltextzugriff (PDF)

In vivo synergy between topoisomerase II and histone deacetylase inhibitors: predictive correlates

Molecular cancer therapeutics, 2005-12, Vol.4 (12), p.1993-2000

2005

Volltextzugriff (PDF)

Randomized Trial of Oral Cyclophosphamide and Veliparib in High-Grade Serous Ovarian, Primary Peritoneal, or Fallopian Tube Cancers, or BRCA-Mutant Ovarian Cancer

Clinical cancer research, 2015-04, Vol.21 (7), p.1574-1582

2015

Volltextzugriff (PDF)

Phase I/II Study of Atrasentan, an Endothelin A Receptor Antagonist, in Combination with Paclitaxel and Carboplatin as First-Line Therapy in Advanced Non–Small Cell Lung Cancer

Clinical cancer research, 2008-03, Vol.14 (5), p.1464-1469

2008

Volltextzugriff (PDF)

1 – 25 von 1.701

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(1.549)
Mit Volltextzugriff
(1.407)

Publikationsform

3 weitere anzeigen...

Weniger anzeigen...

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(1.154)
Life Sciences & Biomedicine
(963)
Humans
(813)
Female
(453)
Male
(418)
Adult
(261)
Middle Aged
(255)
Biological And Medical Sciences
(254)
Medical Sciences
(217)
Animals
(197)
Aged
(191)
Oncology
(141)
Physical Sciences
(115)
Adolescent
(101)
Child
(101)
Risk Factors
(95)
Science & Technology - Other Topics
(94)
Treatment Outcome
(93)
Neurosciences & Neurology
(90)
Multidisciplinary Sciences
(88)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

Blood
(44)
Cancer Research
(35)
Clinical Cancer Research
(34)
Science
(34)
The New England Journal Of Medicine
(28)
The Astrophysical Journal
(27)
Journal Of Clinical Oncology
(25)
Nature
(25)
Nature Communications
(18)
Plos One
(15)

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

Menü

Weitere Dienste

Einstellungen

Nuclear export of proteins and drug resistance in cancer

First-in-Man Clinical Trial of the Oral Pan-AKT Inhibitor MK-2206 in Patients With Advanced Solid Tumors

Randomized multicenter phase 2 study of pomalidomide, cyclophosphamide, and dexamethasone in relapsed refractory myeloma

Phase I Trial of Interleukin-12 Plasmid Electroporation in Patients With Metastatic Melanoma

Canonical Wnt pathway inhibitor ICG-001 induces cytotoxicity of multiple myeloma cells in Wnt-independent manner

Inhibition of Notch signaling induces apoptosis of myeloma cells and enhances sensitivity to chemotherapy

Phase II Study of the Mitogen-Activated Protein Kinase 1/2 Inhibitor Selumetinib in Patients With Advanced Hepatocellular Carcinoma

Treatment of acquired drug resistance in multiple myeloma by combination therapy with XPO1 and topoisomerase II inhibitors

ABCG2 expression, function, and promoter methylation in human multiple myeloma

Valproic acid alters chromatin structure by regulation of chromatin modulation proteins

Human Multiple Myeloma Cells Are Sensitized to Topoisomerase II Inhibitors by CRM1 Inhibition

Spending and Job-Finding Impacts of Expanded Unemployment Benefits: Evidence from Administrative Micro Data

Selective inhibition of matrix metalloproteinase-2 in the multiple myeloma-bone microenvironment

Potentiation of a Topoisomerase I Inhibitor, Karenitecin, by the Histone Deacetylase Inhibitor Valproic Acid in Melanoma: Translational and Phase I/II Clinical Trial

A Phase 1 Escalating Single-Dose and Weekly Fixed-Dose Study of Cetuximab: Pharmacokinetic and Pharmacodynamic Rationale for Dosing

Sequence-specific potentiation of topoisomerase II inhibitors by the histone deacetylase inhibitor suberoylanilide hydroxamic acid

Phase I Trial of Poly-l-Glutamate Camptothecin (CT-2106) Administered Weekly in Patients with Advanced Solid Malignancies

CRM1 Inhibition Sensitizes Drug Resistant Human Myeloma Cells to Topoisomerase II and Proteasome Inhibitors both In Vitro and Ex Vivo

Combined inhibition of Notch signaling and Bcl-2/Bcl-xL results in synergistic antimyeloma effect

CRM1-mediated nuclear export of proteins and drug resistance in cancer

Inhibition of CRM1-dependent nuclear export sensitizes malignant cells to cytotoxic and targeted agents

Novel 5' untranslated region variants of BCRP mRNA are differentially expressed in drug-selected cancer cells and in normal human tissues : Implications for drug resistance, tissue-specific expression, and alternative promoter usage

In vivo synergy between topoisomerase II and histone deacetylase inhibitors: predictive correlates

Randomized Trial of Oral Cyclophosphamide and Veliparib in High-Grade Serous Ovarian, Primary Peritoneal, or Fallopian Tube Cancers, or BRCA-Mutant Ovarian Cancer

Phase I/II Study of Atrasentan, an Endothelin A Receptor Antagonist, in Combination with Paclitaxel and Carboplatin as First-Line Therapy in Advanced Non–Small Cell Lung Cancer

Suchergebnisse filtern